.Merck defeats earnings assumptions, rears sales expectation on tough need for best drugs like Keytruda CNBCMerck & Co. (MRK United States) Defeats Earnings Estimates as Keytruda Purchases Surge BloombergMerck Supply: Pharma Titan Posts Solid Results, However Outlook Drops Short Investor's Business DailyMerck Announces Second-Quarter 2024 Financial End results Yahoo FinanceMerck defeats earnings as well as sales assumptions in the middle of Keytruda advantage, however supplies mixed full-year overview MarketWatch.